Swiss gene-editing specialist CRISPR Therapeutics (Nasdaq: CRSP) and San Diego, USA-based Sirius Therapeutics, which is ...

CRISPR Therapeutics is paying $25 million upfront to work on multiple siRNA targets with Sirius Tx with an early focus on the ...

Collaboration brings together complementary capabilities to co-develop and co-commercialize SRSD107, a next generation, ...

AbbVie and ADARx Pharmaceuticals have announced a multi-billion dollar partnership to develop small interfering RNA (siRNA) ...

GSK has announced a $1.2 billion deal to acquire efimosfermin alfa from Boston Pharmaceuticals, writes John George for the ...

The FDA has approved MSD’s Welireg for rare adrenal tumours, and AbbVie’s Emrelis for treating c-Met+ lung cancer patients.

AbbVie and ADARx Pharmaceuticals have signed a collaboration and license option agreement to develop small interfering RNA ...

AbbVie has claimed its first regulatory approval, from the FDA, for its C-met-targeting antibody-drug conjugate (ADC) Emrelis ...

This marks AbbVie’s second major siRNA deal following its $1.4bn acquisition of Aliada Therapeutics last year.

The Vallabh/Minikel lab at the Broad Institute has selected Argonaut Manufacturing Services, Inc., “Argonaut,” as the drug product manufacturer for a therapeutic compound for a potential clinical ...

FDA grants accelerated approval to AbbVie's Emrelis for c-Met overexpressing NSCLC; siRNA partnership with ADARx includes ...